(See also Causes of Hepatitis Causes of Hepatitis Hepatitis is an inflammation of the liver characterized by diffuse or patchy necrosis. Hepatitis may be acute or chronic (usually defined as lasting > 6 months). Most cases of acute viral hepatitis... read more , Overview of Chronic Hepatitis Overview of Chronic Hepatitis Chronic hepatitis is hepatitis that lasts > 6 months. Common causes include hepatitis B and C viruses, nonalcoholic steatohepatitis (NASH), alcohol-related liver disease, and autoimmune liver... read more , and Acute Hepatitis C Hepatitis C, Acute Hepatitis C is caused by an RNA virus that is often parenterally transmitted. It sometimes causes typical symptoms of viral hepatitis, including anorexia, malaise, and jaundice but may be asymptomatic... read more .)
Hepatitis lasting > 6 months is generally defined as chronic hepatitis, although this duration is arbitrary.
There are 6 major genotypes of hepatitis C virus (HCV), which vary in their response to treatment. Genotype 1 is more common than genotypes 2, 3, 4, 5, and 6; it accounts for 70 to 80% of cases of chronic hepatitis C in the US.
Acute hepatitis C Hepatitis C, Acute Hepatitis C is caused by an RNA virus that is often parenterally transmitted. It sometimes causes typical symptoms of viral hepatitis, including anorexia, malaise, and jaundice but may be asymptomatic... read more becomes chronic in about 75% of patients. The Centers of Disease Control and Prevention (CDC) estimates that about 2.4 million people in the US have chronic hepatitis C infection (1 General references Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more ). Worldwide, 71 million people are estimated to have chronic hepatitis C (2 General references Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more ).
Chronic hepatitis C progresses to cirrhosis Cirrhosis Cirrhosis is a late stage of hepatic fibrosis that has resulted in widespread distortion of normal hepatic architecture. Cirrhosis is characterized by regenerative nodules surrounded by dense... read more in 20 to 30% of patients; cirrhosis often takes decades to appear. Hepatocellular carcinoma Hepatocellular Carcinoma Hepatocellular carcinoma usually occurs in patients with cirrhosis and is common in areas where infection with hepatitis B and C viruses is prevalent. Symptoms and signs are usually nonspecific... read more can result from HCV-induced cirrhosis but results only rarely from chronic infection without cirrhosis (unlike in chronic HBV infection Hepatitis B, Chronic Hepatitis B is a common cause of chronic hepatitis. Patients may be asymptomatic or have nonspecific manifestations such as fatigue and malaise. Diagnosis is by serologic testing. Without treatment... read more ).
Up to 20% of patients with alcohol-related liver disease Alcohol-Related Liver Disease Alcohol consumption is high in most Western countries. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 8.5% of US adults are estimated to have... read more 
harbor HCV. The reasons for this high association are unclear because concomitant alcohol and drug use accounts for only a portion of cases. In these patients, HCV and alcohol act synergistically to worsen liver inflammation and fibrosis.
General references
1. CDC: Hepatitis C questions and answers for health professionals. Accessed 11/29/20.
2. World Health Organization: Hepatitis C. Accessed 11/29/20.
Symptoms and Signs of Chronic Hepatitis C
Many patients are asymptomatic and do not have jaundice, although some have malaise, anorexia, fatigue, and nonspecific upper abdominal discomfort. Often, the first findings are signs of cirrhosis Cirrhosis Cirrhosis is a late stage of hepatic fibrosis that has resulted in widespread distortion of normal hepatic architecture. Cirrhosis is characterized by regenerative nodules surrounded by dense... read more (eg, splenomegaly, spider nevi, palmar erythema) or complications of cirrhosis (eg, portal hypertension Portal Hypertension Portal hypertension is elevated pressure in the portal vein. It is caused most often by cirrhosis (in developed countries), schistosomiasis (in endemic areas), or hepatic vascular abnormalities... read more , ascites Ascites Ascites is free fluid in the peritoneal cavity. The most common cause is portal hypertension. Symptoms usually result from abdominal distention. Diagnosis is based on physical examination and... read more , encephalopathy Portosystemic Encephalopathy Portosystemic encephalopathy is a neuropsychiatric syndrome that can develop in patients with liver disease. It most often results from high gut protein or acute metabolic stress (eg, gastrointestinal... read more ).
Chronic hepatitis C is occasionally associated with lichen planus, mucocutaneous vasculitis, glomerulonephritis Membranoproliferative Glomerulonephritis Membranoproliferative glomerulonephritis is a heterogeneous group of disorders that share mixed nephritic and nephrotic features and microscopic findings. They mostly affect children. Cause... read more 
, porphyria cutanea tarda Porphyria Cutanea Tarda Porphyria cutanea tarda (PCT) is a comparatively common hepatic porphyria affecting mainly the skin. Liver disease is also common. PCT is due to an acquired or inherited deficiency in the activity... read more 
, mixed cryoglobulinemia Cryoglobulinemia Conditions that cause an abnormal protein content in the blood, typically in the form of immunoglobulins, can affect vascular fragility and lead to purpura. (See also Overview of Vascular Bleeding... read more 
, and, perhaps, non-Hodgkin B-cell lymphoma Non-Hodgkin Lymphomas Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the... read more 
. Symptoms of cryoglobulinemia include fatigue, myalgias, arthralgias, neuropathy, glomerulonephritis, and rashes (urticaria, purpura, leukocytoclastic vasculitis); asymptomatic cryoglobulinemia is more common.
Screening for Chronic Hepatitis C
One-time, routine screening is recommended for all people ≥ 18 years old, regardless of risk factors.
One-time screening is recommended for people < 18 years old with the following characteristics (1, 2 Screening references Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more ):
Are currently using or have ever injected illicit drugs, even if only once or only in the distant past
Have used intranasal illicit drugs
Are men who have sex with men
Are currently or have ever been treated with long-term hemodialysis
Have percutaneous or parenteral exposures in an unregulated setting
Have abnormal alanine aminotransferase (ALT) levels or unexplained chronic liver disease
Work in health care or public safety and were exposed to HCV-positive blood through a needlestick, other injury by a sharp object, or mucosal contact
Have HIV infection or are starting preexposure prophylaxis (PrEP) for HIV
Have ever been incarcerated
Are children born to HCV-infected women
Such testing is important because symptoms may not develop until the hepatitis C has extensively damaged the liver, years after the initial infection.
Screening references
1. American Association for the Study of Liver Disease and the Infectious Disease Society of America (IDSA): HCV testing and linkage to care. Accessed 11/29/20.
2. CDC: Testing recommendations for hepatitis C virus infection. Accessed 11/29/20.
Diagnosis of Chronic Hepatitis C
Serologic testing
HCV RNA
(See also the American Association for the Study of Liver Disease’s and the Infectious Diseases Society of America's practice guideline Hepatitis C Guidance 2019 Update: AASLD-IDSA (Infectious Diseases Society of America) recommendations for testing, managing, and treating hepatitis C virus infection and the U.S. Preventive Services Task Force’s clinical guideline Hepatitis C virus infection in adolescents and adults: Screening.)
The diagnosis Diagnosis Chronic hepatitis is hepatitis that lasts > 6 months. Common causes include hepatitis B and C viruses, nonalcoholic steatohepatitis (NASH), alcohol-related liver disease, and autoimmune liver... read more of chronic hepatitis C is suspected in patients with any of the following:
Suggestive symptoms and signs
Incidentally noted elevations in aminotransferase levels
Previously diagnosed acute hepatitis
Diagnosis is confirmed by finding positive anti-HCV and positive HCV RNA ≥ 6 months after initial infection (see table Hepatitis C Serology Hepatitis C Serology Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more ).
Liver biopsy is useful for one or more of the following:
Grading inflammatory activity
Staging fibrosis
Excluding other causes of liver disease
However, the role of liver biopsy is evolving in hepatitis C, and biopsy is being supplanted by noninvasive imaging (eg, ultrasound elastography, magnetic resonance elastography) and serum markers of fibrosis, as well as scoring systems for fibrosis based on serologic markers.
HCV genotype is determined before treatment because genotype influences the course, duration, and success of treatment.
HCV RNA detection and quantification is used to help diagnose hepatitis C and to evaluate treatment response during and after treatment. For most currently available quantitative HCV RNA assays, the lower limit of detection is at least < 50 IU/mL. If a quantitative assay does not have that level of sensitivity, a qualitative assay can be used. Qualitative assays can detect very low levels of HCV RNA, often as low as < 10 IU/mL, and provide results as positive or negative. Qualitative tests can be used to confirm a diagnosis of hepatitis C or a sustained virologic response (SVR), defined as no detectable HCV RNA at 12 weeks after completion of treatment.
Other tests
Liver tests are needed if not previously done; they include serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase.
Other tests should be done to evaluate liver function; they include serum albumin, bilirubin, platelet count, and prothrombin time/international normalized ratio (PT/INR).
Patients should be tested for HIV Diagnosis Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... read more 
and hepatitis B infection Diagnosis Hepatitis B is caused by a DNA virus that is often parenterally transmitted. It causes typical symptoms of viral hepatitis, including anorexia, malaise, and jaundice. Fulminant hepatitis and... read more because transmission of these infections is similar.
If symptoms or signs of cryoglobulinemia develop during chronic hepatitis C, cryoglobulin levels and rheumatoid factor should be measured; high levels of rheumatoid factor and low levels of complement suggest cryoglobulinemia.
Screening for complications
Patients with chronic HCV infection and advanced fibrosis or cirrhosis should be screened every 6 months for hepatocellular cancer Diagnosis Hepatocellular carcinoma usually occurs in patients with cirrhosis and is common in areas where infection with hepatitis B and C viruses is prevalent. Symptoms and signs are usually nonspecific... read more with ultrasonography and serum alpha-fetoprotein measurement, although the cost-effectiveness of this practice, particularly serum alpha-fetoprotein measurement, is debated.
Prognosis for Chronic Hepatitis C
Prognosis depends on whether patients have a sustained virologic response (SVR), ie, no detectable HCV-RNA at 12 weeks after completion of treatment.
Patients who have an SVR have a > 99% chance of remaining HCV RNA–negative and are typically considered cured. Nearly 95% of patients with an SVR have improved histologic findings, including fibrosis and histologic activity index; in addition, risk of progression to cirrhosis, hepatic failure, and liver-related death is reduced. In patients who have cirrhosis and portal hypertension and who were treated with interferon-based regimens, an SVR has been shown to reduce portal pressures and significantly reduce risk of hepatic decompensation, liver-related death, all-cause mortality, and hepatocellular carcinoma (1 Prognosis reference Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more ).
Likelihood of achieving an SVR with direct-acting antiviral regimens seems to depend mostly on the following:
Degree of liver fibrosis
Response to prior treatment
HCV genotype
Prognosis reference
1. van der Meer AJ, Veldt BJ, Feld JJ, et al: Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (24):2584–2593, 2012.
Treatment of Chronic Hepatitis C
Direct-acting antiviral drugs
Overview of HCV treatment
(See also the American Association for the Study of Liver Disease’s [AASLD] practice guidelines Recommendations for testing, managing, and treating hepatitis C and the AASLD/Infectious Disease Society of America's [IDSA] When and in whom to initiate HCV therapy.)
For chronic hepatitis C, treatment is recommended for all patients, except those with a short life expectancy due to comorbid conditions that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy.
The goal of treatment is permanent elimination of HCV RNA (ie, SVR), which is associated with permanent normalization of aminotransferase levels and cessation of histologic progression. Treatment results are more favorable in patients with less fibrosis than in patients with cirrhosis.
Until late 2013, all genotypes were treated with pegylated interferon alfa plus ribavirin. Now, interferon-based treatment regimens are no longer used, and ribavirin is no longer considered first-line and is used only in certain alternative regimens. Currently, all patients are treated with direct-acting antivirals (DAAs) that affect specific HCV targets, such as proteases or polymerases (see also HCV genotype 1 HCV genotype 1 Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more and HCV genotypes 2,3, 4, 5, and 6 HCV genotypes 2, 3, 4, 5, and 6 Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more ).
Pearls & Pitfalls
|
DAAs currently used to treat HCV include
Simeprevir: A 2nd-generation genotype 1–specific protease inhibitor
Sofosbuvir: A polymerase inhibitor with activity against HCV genotypes 1 to 6
Paritaprevir: A protease inhibitor
Ledipasvir: A protease inhibitor
Dasabuvir: A polymerase inhibitor
Ombitasvir: An inhibitor of the viral nonstructural protein 5A (NS5A inhibitor)
Daclatasvir: An NS5A inhibitor
Elbasvir: An NS5A inhibitor
Grazoprevir: A protease inhibitor
Velpatasvir: An NS5A inhibitor used to treat all HCV genotypes
Glecaprevir: A protease inhibitor used to treat all HCV genotypes
Pibrentasvir: An NS5A inhibitor used to treat all HCV genotypes
Voxilaprevir: An NS3/4A protease inhibitor
DAAs are not used as single drugs but are used in specific combinations to maximize efficacy.
Sofosbuvir is given in combination with other drugs. The preferred combinations include
Ledipasvir in a single pill to treat HCV genotypes 1, 4, 5 and 6
Velpatasvir in a single pill to treat HCV genotypes 1 through 6
Velpatasvir and voxilaprevir in a single pill to treat HCV genotypes 1 through 6
Sofosbuvir can also be given with ribavirin (for genotypes 1 through 6), simeprevir (for genotype 1), or daclatasvir (for genotypes 1 through 3) in all-oral regimens, but these regimens are not preferred.
The single pill containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg orally once a day for 12 weeks is used for re-treatment of chronic HCV infection in adults who have genotype 1, 2, 3, 4, 5, or 6 and were previously treated with a regimen containing an NS5A inhibitor or who have genotype 1a or 3 and were previously treated with a regimen containing sofosbuvir without an NS5A inhibitor (1 Treatment references Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more ). This combination pill (sofosbuvir, velpatasvir, and voxilaprevir) is not recommended for patients with moderate or severe hepatic impairment, and no dosage can be recommended for patients with severe renal impairment.
Elbasvir/grazoprevir in a single pill is used to treat HCV genotypes 1 and 4.
Glecapravir and pibrentasvir are available in a single pill to treat HCV genotypes 1 through 6.
The following 5-drug regimen, although not preferred, is effective against genotypes 1 and 4:
Paritaprevir/ritonavir/ombitasvir (in a single pill) given once a day
Dasabuvir, given twice a day
Ribavirin, given twice a day
Paritaprevir/ritonavir/ombitasvir plus dasabuvir, although not preferred, is available in a single package for genotypes 1 and 4.
Ritonavir increases levels of paritaprevir but has no direct antiviral activity.
Current recommendations for HCV treatment are evolving rapidly. Hepatitis C Guidance 2019 Update: AASLD-IDSA (Infectious Diseases Society of America) recommendations for testing, managing, and treating hepatitis C virus infection from the American Association for the Study of Liver Disease (AASLD) and the Infectious Diseases Society of America (IDSA), available online, are updated frequently.
Decompensated cirrhosis due to hepatitis C is the most common indication for liver transplantation Liver Transplantation Liver transplantation is the 2nd most common type of solid organ transplantation. (See also Overview of Transplantation.) Indications for liver transplantation include Cirrhosis (70% of transplantations... read more in the US. HCV recurs almost universally in the graft. Before the use of DAAs, patient and graft survival was less favorable than when transplantation is done for other indications. However, when DAAs are used, the SVR rate in patients who have had a liver transplant exceeds 95% whether they have cirrhosis or not. Because SVR rates are so high, transplantation of hepatitis C–positive organs is being done increasingly, particularly among recipients who are also hepatitis C–positive, thus expanding the pool of potential donors. If the recipient and donor are hepatitis C–positive, treatment can be postponed until after transplantation. As a result, an unnecessary pretransplantation course of treatment can be avoided.
Regimens of elbasvir/grazoprevir or glecaprevir/pibrentasvir are now considered to have a good safety profile and are effective in patients with end-stage kidney disease, including dialysis patients.
Treatment of hepatitis C in patients with decompensated cirrhosis should be done in consultation with hepatologists, ideally in a liver transplant center. HCV regimens that include protease inhibitors should not be used in patients with decompensated cirrhosis because levels of protease inhibitors are increased in patients with hepatic dysfunction.
Hepatitis B reactivation resulting in liver failure and death has been reported during or after HCV treatment with DAAs. Therefore, all patients with hepatitis C being treated with DAAs should be checked for evidence of chronic or prior hepatitis B; tests should include all of the following:
Hepatitis B surface antigen (HBsAg)
Hepatitis B surface antibody (anti-HBs)
IgG antibody to hepatitis B core (IgG anti-HBc)
Patients with chronic hepatitis B or evidence of prior hepatitis B should be monitored for reactivation during and after HCV treatment, and HBV antiviral therapy Treatment Hepatitis B is a common cause of chronic hepatitis. Patients may be asymptomatic or have nonspecific manifestations such as fatigue and malaise. Diagnosis is by serologic testing. Without treatment... read more should be considered during the course of HCV treatment.
HCV genotype 1
Genotype 1 is more resistant to traditional treatment with dual therapy with pegylated interferon-alpha plus ribavirin than other genotypes. However, now with the use of interferon-free regimens of direct-acting antivirals (DAAs), the rate of SVR has increased from < 50% to ≥ 95%.
First-line regimens for HCV genotype 1 include
Ledipasvir/sofosbuvir
Elbasvir/grazoprevir
Velpatasvir/sofosbuvir
Glecaprevir/pibrentasvir
Fixed-dose combination of ledipasvir 90 mg/sofosbuvir 400 mg is given orally once a day for 8 to 12 weeks depending on history of prior treatment, pretreatment viral load, and degree of liver fibrosis.
Fixed-dose combination of elbasvir 50 mg/grazoprevir 100 mg is given orally once a day, with or without ribavirin 500 to 600 mg orally twice a day, for 12 to 16 weeks depending on history of prior treatment, degree of liver fibrosis, and, in patients with genotype 1a, the presence or absence of baseline NS5A resistance–associated variants to elbasvir.
Fixed-dose combination of velpatasvir 100 mg/sofosbuvir 400 mg is given orally once a day for 12 weeks.
Fixed-dose combination of glecaprevir 300 mg/pibrentasvir 120 mg is given orally once a day for 8 to 16 weeks, depending on history of prior treatment and degree of liver fibrosis.
Alternative regimens for HCV genotype 1 include
A 5-drug regimen using the fixed-dose combination of paritaprevir 150 mg/ritonavir 100 mg/ombitasvir 25 mg once a day plus dasabuvir 250 mg orally twice a day and ribavirin 500 to 600 mg orally twice a day for 12 to 24 weeks depending on degree of liver fibrosis
Sofosbuvir 400 mg orally once a day plus simeprevir 150 mg orally once a day, with or without ribavirin 500 to 600 mg orally twice a day, for 12 to 24 weeks, depending of degree of liver fibrosis
Sofosbuvir 400 mg orally once a day plus daclatasvir 60 mg orally once a day, with or without ribavirin 500 to 600 mg orally twice a day, for 12 to 24 weeks, depending on degree of liver fibrosis and history of prior treatment
Simeprevir can cause anemia and photosensitivity. All protease inhibitors have drug-drug interactions.
Ribavirin is usually well-tolerated but commonly causes anemia due to hemolysis; dosage should be decreased if hemoglobin decreases to < 10 g/dL (100 g/L). Ribavirin is teratogenic in both men and women, requiring contraception during treatment and for 6 months after treatment is completed.
HCV genotypes 2, 3, 4, 5, and 6
For genotype 2, one of the following combinations is recommended:
Fixed-dose combination of sofosbuvir 400 mg/velpatasvir 100 mg once a day for 12 weeks
Fixed-dose combination of glecaprevir 300 mg/pibrentasvir 120 mg once a day for 8 to 12 weeks, depending on history of prior treatment and degree of liver fibrosis (2 Treatment references Hepatitis C is a common cause of chronic hepatitis. It is often asymptomatic until manifestations of chronic liver disease occur. Diagnosis is confirmed by finding positive anti-HCV and positive... read more )
An alternative regimen for genotype 2 is
Sofosbuvir 400 mg orally once a day plus daclatasvir 60 mg orally once a day for 12 to 24 weeks, depending on the degree of liver fibrosis
For genotype 3, first-line treatments include
Fixed-dose combination of sofosbuvir 400 mg/velpatasvir 100 mg once a day for 12 weeks
Fixed-dose combination of glecaprevir 300 mg/pibrentasvir 120 mg once a day for 8 to 16 weeks, depending on history of prior treatment and degree of liver fibrosis
An alternative regimen for genotype 3 is
Sofosbuvir 400 mg orally once a day plus daclatasvir 60 mg orally once a day with or without ribavirin 500 to 600 mg orally twice a day for 12 to 24 weeks depending on degree of liver fibrosis
For genotype 4, first-line treatments include
Fixed-dose combination of ledipasvir 90 mg/sofosbuvir 400 mg orally once a day for 12 weeks
Fixed-dose combination of elbasvir 50 mg/grazoprevir 100 mg orally once a day for 12 weeks
Fixed-dose combination of velpatasvir 100 mg/sofosbuvir 400 mg once a day for 12 weeks
Fixed-dose combination of glecaprevir 300 mg/pibrentasvir 120 mg once a day for 8 to 12 weeks, depending on degree of liver fibrosis
An alternative regimen for genotype 4 is
Fixed dose combination of paritaprevir 150 mg/ritonavir 100 mg/ombitasvir 25 mg orally once a day plus ribavirin 500 to 600 mg orally twice a day for 12 to 16 weeks
For genotypes 5 and 6, first-line treatments include
Fixed-dose combination of ledipasvir 90 mg/sofosbuvir 400 mg orally once a day for 12 weeks
Fixed-dose combination of velpatasvir 100 mg/sofosbuvir 400 mg once a day for 12 weeks
Fixed-dose combination of glecaprevir 300 mg/pibrentasvir 120 mg once a day for 8 to 12 weeks, depending on degree of liver fibrosis
Treatment references
1. Bourlière M, Gordon SC, Flamm SL, et al: Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376 (22):2134-2146, 2017. doi: 10.1056/NEJMoa1613512
2. Asselah T, Kowdley KV, Zadeikis N, et al: Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 16 (3):417–426, 2018. doi: 10.1016/j.cgh.2017.09.027 Epub 2017 Sep 22
Key Points
Chronic hepatitis C infection develops in 75% of patients with acute infection and leads to cirrhosis in 20 to 30%; some patients with cirrhosis develop hepatocellular carcinoma.
Diagnosis is confirmed by finding positive anti-HCV and positive HCV RNA.
Treatment varies by genotype but includes use of one or more direct-acting antiviral drugs, sometimes with ribavirin.
Pegylated interferon is no longer recommended for treatment of chronic hepatitis C.
New treatments can permanently eliminate HCV RNA in > 95% of patients.
Patients with decompensated cirrhosis should be treated by hepatologists, and regimens containing protease inhibitors should not be used.
More Information
AASLD-IDSA Hepatitis C Guidance Panel: Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America (ISDA) Recommendations for Testing,Managing, and Treating Hepatitis C Virus Infection. This web site provides up-to-date, peer-reviewed, unbiased,evidence-based recommendations to help clinicians make decisions about the testing, management, and treatment of HCV infection.
American Association for the Study of Liver Disease and the Infectious Disease Society of America (IDSA): When and in whom to initiate HCV therapy: This web site discusses the clinical benefits of curing hepatitis C and of treating fibrosis early, the importance of pretreatment assessment, and considerations in specific populations. It also includes an overview of cost, reimbursement, and cost-effectiveness for hepatitis C treatment regimens.
U.S. Preventive Services Task Force: Hepatitis C virus infection in adolescents and adults: Screening: This web site discusses the importance of screening, assessment of risk, use of screening tests including intervals, and treatment and provides supporting evidence.
